Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Operating Margin (2016 - 2025)

Historic Operating Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 32.29%.

  • Theravance Biopharma's Operating Margin rose 319500.0% to 32.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.85%, marking a year-over-year increase of 287600.0%. This contributed to the annual value of 72.92% for FY2024, which is 246600.0% up from last year.
  • Latest data reveals that Theravance Biopharma reported Operating Margin of 32.29% as of Q3 2025, which was up 319500.0% from 10.4% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Operating Margin registered a high of 10.4% during Q2 2025, and its lowest value of 1540.08% during Q1 2022.
  • Over the past 5 years, Theravance Biopharma's median Operating Margin value was 110.16% (recorded in 2024), while the average stood at 248.83%.
  • Per our database at Business Quant, Theravance Biopharma's Operating Margin skyrocketed by 42433100bps in 2021 and then tumbled by -9516500bps in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Operating Margin stood at 375.8% in 2021, then skyrocketed by 68bps to 119.0% in 2022, then soared by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then skyrocketed by 34bps to 32.29% in 2025.
  • Its last three reported values are 32.29% in Q3 2025, 10.4% for Q2 2025, and 93.8% during Q1 2025.